Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

WORLD Symposium Notebook: New Data In Lysosomal Diseases And A Push For Earlier Testing

Executive Summary

The WORLD Symposium Feb. 13 to 16 in San Diego offered everything from basic research through late-stage clinical data in lysosomal diseases, including ArmaGen's blood-brain barrier-crossing treatment for Hurler syndrome and updates from ongoing development programs from rare disease specialists, such as Genzyme, Amicus and Protalix.

Advertisement

Related Content

Shire’s Sales, R&D Heads Shed Light On The Post-Baxalta Road Ahead
10 Approvals To Watch For In Early 2017
J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
PIPELINE WATCH: Phase III Trials Start In Atypical HUS, Fabry Disease And Colorectal Cancer
Video Interview: Abeona Breaking Into Rare Diseases
FDA deems Sanofi/Genzyme drug olipudase alfa 'breakthrough'
'In transition' Shire strikes deal for follow-on Hunter syndrome product
ArmaGen taps Big Pharma interest in 'Trojan horse' tech to get drugs into brain

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel